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Alzheimer’s disease (AD) is a scourge of longevity that will drain enormous resources from 21 
public health budgets in the future. Currently, there is no diagnostic biomarker and/or 22 
treatment for this most common form of dementia in humans. AD can be of early familial-23 
onset or sporadic with a late-onset. Apart from the two main hallmarks, amyloid-beta and the 24 
neurofibrillary tangles, inflammation is a characteristic feature of AD neuropathology. 25 
Inflammation may be caused by a local central nervous system insult and/or by peripheral 26 
infections. Numerous microorganisms are suspected in AD brains ranging from bacteria 27 
(mainly oral and non-oral Treponema species), viruses (Herpes simplex type I) and yeasts 28 
(Candida species). A causal relationship between periodontal pathogens/non-oral Treponema 29 
species of bacteria has been proposed via the amyloid-beta and inflammatory links. 30 
Periodontitis constitutes a peripheral oral infection that can provide the brain with intact 31 
bacteria and virulence factors and inflammatory mediators due to daily, transient 32 
bacteraemias. If and when genetic risk factors meet environmental risk factors in the brain, 33 
disease is expressed, in which neurocognition may be exacerbated impacted, leading to the 34 
of dementia. To achieve the goal of finding a diagnostic biomarker and possible prophylactic 35 
treatment for AD, there is an initial need to solve the etiological puzzle contributing to its 36 
pathogenesis. This review therefore addresses oral infection as the plausible aetiology of late 37 
onset AD (LOAD). the plausible aetiology of the late-onset AD being an oral infection.  38 
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Alzheimer’s disease (AD) is a neurodegenerative disease and the most common example of a 42 
group of diseases that manifest as dementia. It is associated with atrophy and specific 43 
neuronal death particularly in the hippocampal region of the brain (1).  Research into AD 44 
pathogenesis, has flagged two main categories of the disease. A: the familial-onset  onset 45 
that accounts for around 2% of all AD cases and the sporadic form of late-onset AD also 46 
to as LOAD that constitutes approximately 98% of the cases. LOAD displays genetic 47 
susceptibility traits of which the well-known risk factor is inheritance of the apolipoprotein 48 
(APOEɛ4) gene allele (2) and, appears to require an environmental factor for disease 49 
expression. For example a pathogen-host interaction, can exacerbate neurocognition in some 50 
elderly individuals who if in their 80+ years likely become diagnosed with LOAD (3, 4). The 51 
rationale for this review therefore is to try to explain the aetiology in the vast proportion of 52 
LOAD cases that relies upon common risk factors, and to date, .several. Several scientists 53 
these to be peripheral infections (5-11), and the accompanying systemic and local 54 
inflammatory mediators (11-13). Of these, the plausible risk from oral infection is the main 55 
focus of this review. 56 
   57 
PREVALENCE OF AD 58 
AD is a scourge burden of longevity resulting from the superior quality of health care 59 
This factor is likely to contribute to quadrupling of AD subjects living in our society during 60 
the next 40 years (14). It is estimated that by 2050 about 13-14 million people are likely to 61 
suffer from AD in the USA with a rise in the total costs estimated to be more than $1 trillion. 62 
The odds of having a diagnosis of AD when over 85 years of age exceed 1:3 (15). One in six 63 
people over 80 years in the UK have has dementia (16). Estimates for the prevalence of AD in 64 
USA indicate that more than 5 million individuals who are 65 years or older currently suffer 65 
from AD (1, 15). About 200,000 subjects have been diagnosed with the early-onset familial 66 
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AD form and health care costs for this disease are about $200 billion per year (1). It is clear 67 
that AD is fast becoming a major health challenge in the USA and around the globe that will 68 
financially drain public health budgets and care giver services. 69 
 70 
NEUROPATHOLOGICAL CHARACTERISTICS OF THE AD BRAIN 71 
The AD brain is characterized by several neuropathological features of which two seminal 72 
hallmarks (Fig. 1) arise from proteostasis of the ongoing neurodegenerative processes and are 73 
essential for a definitive diagnosis of the disease at post mortem (17). One of the hallmark 74 
proteins is made up of fibrils in the form of extracellular, insoluble plaques and consists 75 
primarily of amyloid-beta (Aβ) (18). These peptide deposits in variable sizes depend upon the 76 
secretase enzymes (α-, β - and ϒ-secretases) that cleave it from the longer amyloid precursor 77 
protein (APP). Initial reports suggested fibrillar Aβ to be neurotoxic (19) as it has been shown 78 
to kill all types of cells by apoptosis induction (20). However, there are two known insoluble 79 
fibrillar Aβ amyloid peptides comprised of Aβ40 and Aβ42 amino-acid residues as well as their 80 
different which exhibit distinct physiological states within the human brain. There is a general 81 
consensus among scientists that the larger (Aβ42) peptide is the neurotoxic form as the ageing 82 
brain of cognitive intact individuals also displays Aβ plaques. However, in the cognitively 83 
intact brain they are fewer in number and usually of the diffuse Aβ40 type that appears not to 84 
bear any, as yet known, pathological significance in the elderly who age successfully.. In 85 
monomeric, dimeric and the multimeric forms of Aβ (21). The relative neurotoxicity of these 86 
isoforms remains unclear It is not clear as to which one of these is more neurotoxic (22).  87 
More recently, the fibrillary forms of the Aβ(40/42) peptides released in the AD brain are were 88 
also recognized as “defensin” or innate immune defense molecules that act to protect the host 89 
against infection (23). For example, both of the aforementioned amyloidogenic peptides can 90 
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bind to bacterial membranes and in that way lyse bacterial cells. Although Aβ is acting as an 91 
antimicrobial peptide (AMP), it may be a part of the brain’s ancient/modern innate immune 92 
defense mechanism. AMPs are potent, broad-spectrum, pore-forming agents against targeting 93 
Gram-negative and Gram-positive bacteria, enveloped viruses and protozoans (23), thereby 94 
supporting the hypothesis that AD has an infectious origin.  95 
 96 
Furthermore, the senile plaques (Aβ42) are recognized as triggers that stimulate activation of 97 
microglial cells and initiate local immune responses (24). Activated microglia are the most 98 
important contributors of inflammation in the central nervous system (CNS) (25). They 99 
secrete a number of proinflammatory cytokines (24-26) and recognize pattern associated 100 
molecular patterns (PAMPs) on bacteria and their cellular debris (27-30) to deal with in 101 
response to CNS infection.  102 
The other pathological characteristic of AD is an accumulation of intracellular 103 
hyperphosphorylated tau and heat shock proteins constituting the neurofibrillary tangles 104 
(NFTs). Hyperphosphorylated tau protein alters the polymerization and stability of 105 
microtubules compromising their function (31). NFTs in AD reflect the severity of disease; 106 
however, the significance of pathogen-host interaction to the occurrence of NFTs in the AD 107 
brain is poorly understood. Current genetic evidence is pointing to aberrant innate immune 108 
responses (32, 33) and cholesterol lipid genes (see 34) having greater significance in AD 109 
pathogenesis. A dysfunctional immune system and predisposition to hyperlipidaemia also 110 
support the role of reduced blood flow due to the vascular lesions and inflammation, Aβ 111 
deposition and microorganisms in AD.   112 
In advanced AD pathology, synaptic dysfunction is another structural defect associated with a 113 
decline in memory (35-37). Although a circular argument, malnutrition plays a role in the 114 
gradual loss of synapses and fewer teeth during life is a known risk factor for AD (38). 115 
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Neurons are capable of responding to injury by expressing multiple neurotransmitters. In AD, 116 
selective loss of cholinergic neurons in the basal forebrain (39) also correlates with the loss of 117 
cognitive function (18, 35).  118 
 119 
THE AMYLOID CASCADE HYPOTHESIS  120 
Several hypotheses have been launched for advanced regarding the development of AD. The 121 
amyloid cascade hypothesis serves as a model particularly for the familial form of AD (40) 122 
which is a disease caused by mutations involving the amyloid-β protein precursor, located on 123 
chromosome 21 and presenilin 1 and 2 on chromosomes 14 and 1 respectively that enhance 124 
the APP gene processing towards Aβ deposition (41, 42). The model, which was first 125 
proposed by Glenner and Wong (43), maintains that the neurodegenerative disease is due to 126 
an imbalance between the generation and clearance of Aβ. Genome wide association studies 127 
(GWAS) highlighted the complement receptor 1 (CR1) gene playing a role in AD 128 
pathogenesis (44). One recognized role of CR1, a membrane bound regulatory protein, is its 129 
ability to bind C3b opsonins (Fig. 2). It is abundantly expressed especially on erythrocyte 130 
membranes and as such participates in immune complex clearance by transporting waste to 131 
the liver and the spleen. As the CR1 gene is a risk factor for LOAD, this suggests loss of 132 
function as a possibility for the defective clearance of Aβ in the brain. Other tentative 133 
explanations suggest variation in CR1 protein isoforms (longer and shorter forms) (45), 134 
whereby the longer form is somehow negatively less involved in the disease process via its 135 
ability to bind more C3b and facilitate more effective clearance of Aβ in the brain (46). This 136 
is a process that inevitably fails favouring disease expression with more Aβ proteostasis 137 
buildup and complement pathway activation. The amyloid hypothesis has been modified 138 
several times, particularly due to the finding that soluble oligomers of Aβ may contribute to 139 
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early preclinical stages of the disease that initiate the cascade leading to synaptic dysfunction, 140 
atrophy and neuronal loss (47).  141 
 142 
THE INFLAMMATORY HYPOTHESIS  143 
The intrinsic model 144 
Currently there are two models of the inflammatory hypothesis of AD, an intrinsic and an 145 
extrinsic. The intrinsic inflammation model accounts for the intact “blood-brain barrier” 146 
(BBB) restricting entry of neurotoxic immune molecules and systemic lymphocytes to the 147 
brain.  As a consequence, the brain glial cells are able to generate a local and complete innate 148 
immune system when challenged by foreign agents (26, 48-50). Historically, 149 
neuroinflammation has largely been viewed as being a downstream consequence of the 150 
amyloid hypothesis, whereby the presence of amyloidogenic peptides result in the activation 151 
of microglia initiating pro-inflammatory cascades and the release of potentially neurotoxic 152 
substances resulting in degenerative changes in neurons. GWAS now implicates innate 153 
immune genes (44, 51) as being a risk factor and supports a primary role for the inflammatory 154 
elements of AD pathology via inappropriate activation of the complement system (52-54) in 155 
association with Aβ plaques and NFTs (55).  156 
 157 
The extrinsic model 158 
The extrinsic model accounts for communication of the glial cells with the immune challenges 159 
presented via the blood vascular system using the circumventricular organs and the choroid 160 
plexus that are devoid of the BBB (56). The cells from this region of the brain are fully 161 
equipped with the CD14 receptor and the toll-like receptor 4 (TLR 4) to recognise recognize 162 
the peripheral blood circulation (27, 28). Hence, elements of systemic infections such as those 163 
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originating from Gram-negative, highly virulent oral pathogens, bronchopneumonia and 164 
urinary tract infections (3, 4, 7, 57, 58) reach all organs including the CNS. The consequences 165 
products entering the bloodstream trigger the are that the innate immune responses of hosts’ 166 
pattern recognition receptors (PPR) and TLRs via pattern recognition receptors (PRR) and 167 
infectious threat by secreting to the threat of infection by secreting immune mediators 168 
agents. Increased risk of dementia in the elderly following multiple infectious episodes has 169 
been reported It is reported that multiple episodes of infections in the elderly likely end up 170 
being diagnosed with dementia (4). In addition, systemic infections appear to contribute 171 
towards delirium in some clinically diagnosed AD patients and such episodes can exacerbate 172 
a premorbid cognitive status (3). Holmes et al. proposed that since cytokines are primary 173 
mediators released by the host to defend against infection, such secondary stimuli (IL-1β and 174 
TNF-α) may mediate their effect on the brain and indirectly contribute to cognitive decline (3, 175 
57).  176 
 177 
NON-ORAL BACTERIA RELATED TO AD 178 
Honjo et al. (59) using Bradford Hill’s criteria for assessing the relationship between bacteria 179 
and disease found Chlamydophila pneumoniae to be a likely infectious agent related to the 180 
pathogenesis of AD. Maheshwari and Eslick (60) reported a strong correlation between C. 181 
pneumoniae and AD, and according to Shima et al. (61) C. pneumoniae is currently the most 182 
plausible of all infectious agents proposed to be involved in AD. Lim et al. (62) suggested that 183 
the pro- and chronic inflammatory states in AD pathogenesis may in part be due to C. 184 
pneumoniae infection of monocytes. C. pneumoniae antibodies from typical intracellular and 185 
atypical C. pneumoniae antigens have been identified both from typical intracellular and 186 
of the brains from AD patients (63). Amyloid deposit and NFTs were detected in the same 187 
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regions in apposition to one another suggesting that C. pneumoniae infection is involved in 188 
the development of AD pathology. 189 
Using various techniques Balin et al. (9) found C. pneumoniae in 80-90% of LOAD brain 190 
tissue specimens. C. pneumoniae infection was correlated with the APOEɛ4 allele expression. 191 
The same researchers subsequently demonstrated that astroglia, microglia, neurons, 192 
endothelial cells and monocytes in the LOAD brain are permissive to this bacterium. The 193 
mechanisms of pathogenesis differ between actively- and persistently-infecting chlamydiae 194 
and it is in the persistent state that these organisms cause chronic disease (64, 65). C. 195 
pneumoniae was cultured from two AD brain samples after one or two passages in HEp-2 196 
cells (66). Interestingly, the study indicated that brain isolates were more related to respiratory 197 
than to vascular/atheroma strains of C. pneumoniae. This suggested that C. pneumoniae 198 
infection of the brain was secondary to bronchopneumonia and at the end stages of LOAD. 199 
It has been suggested that the phages phiCPAR39 and phiCPG1, associated with C. 200 
pneumoniae, may enter mitochondria of the bacterial host and work as slow viruses initiating 201 
AD (67). These authors hypothesized that mitochondrial recruitment by C. pneumoniae 202 
phages may be the primary initiating event in the pathogenesis of neurodegenerative 203 
disorders. 204 
In a meta-analysis based on 25 relevant, primarily case-control studies Maheshwari and Eslick 205 
(60) found a statistically significant association between AD and detectable evidence of 206 
infection caused by C. pneumoniae or spirochetes. They reported over a ten-fold increased 207 
occurrence of AD when there was evidence of spirochetal infection (OR: 10.61; 95% CI: 208 
3.38-33.29) and over a four-fold increased occurrence of AD with a conservative risk estimate 209 
(OR: 4.45; 95% CI: 2.33-8.52). There was a five-fold increase in occurrence of AD with C. 210 
pneumoniae infection (OR: 5.66; 95% CI: 1.83-17.51). Accordingly, a strongly positive 211 
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association between bacterial infection and AD was shown for both types of bacteria, but it 212 
was strongest for spirochetes. 213 
It is generally accepted that the syphilis spirochete Treponema pallidum can cause chronic 214 
neuropsychiatric disorders including dementia as well as other neurodegenerative disorders 215 
(11). T. pallidum causes brain atrophy and Aβ deposition in the atrophic form of general 216 
paresis (68, 69) and is a strong indication for involvement of spirochetes in AD pathogenesis. 217 
Chronic diseases such as syphilis are frequently associated with deposition of amyloid (68, 218 
69). Actually, amyloid is considered as Amyloid is an integral part component of spirochetes 219 
which may contribute to amyloid deposition in AD (70). Syphilis accumulation of spirochetes 220 
Spirochete accumulation in the cerebral cortex in the context of syphilis will also lead to 221 
formation of senile plaques, NFTs and granulovacuolar degeneration (71).  222 
Miklossy (68, 69) analyzed data on the ability of spirochetes to induce pathological and 223 
biological hallmarks of AD in vitro following Koch’s and Hill’s postulates and demonstrated 224 
a plausible causal relationship between neurospirochetosis and AD. The data revealed a 225 
statistically significant association between spirochetes and AD (P = 1.5 x 1017, OR = 20, 226 
95% CI = 8-60, N = 247).  When mammalian cells were exposed to spirochetes, the 227 
pathological and biological hallmarks of AD were reproduced in vitro (68, 69). Miklossy (72) 228 
also found that historical Historical observations supported the conclusion that  that 229 
observations paved the way for drawing conclusions such as chronic spirochetal infections 230 
can cause dementia and reproduce the neuropathological hallmarks of AD (72). According to 231 
Miklossy (72), these observations represent further evidence in support of a causal 232 
relationship between various spirochetal infections and AD. 233 
Another spirochete also implicated in AD is, Borrelia burgdorferi, has also been implicated in 234 
AD. This is the causative agent of Lyme disease  which is which is transfected to humans via 235 
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tick vectors through infected tick bites. There are great similarities in the clinical and 236 
syphilis and Lyme disease (72, 73). The occurrence of B. burgdorferi in the brains of AD 237 
patients was first reported by MacDonald and Miranda (74) and was confirmed later by 238 
MacDonald (75, 76), Riviere et al. (5) and Miklossy et al. (77). Interestingly, Bu et al. (78) 239 
found that the infectious burden consisting of B. burgdorferi, C. pneumoniae, Helicobacter 240 
pylori, cytomegalovirus cytomegalo virus and Herpes simplex-1 (HSV-1) is associated with 241 
Gutacker et al. (79) and Pappolla et al. (80) found no evidence for an association between B. 242 
burgdorferi and AD. 243 
Among other bacterial species, H. pylori alone (monoinfection) has been found to be related 244 
to AD (59). These authors suggested that AD pathology can be initiated and exacerbated by 245 
some microorganisms with inflammatory and oxidative responses which may affect the brain 246 
continuously and gradually over time. However, the H. pylori status did not depend on was 247 
not associated with AD in a study from Japan, probably due to the high prevalence of the 248 
organism in controls (81). This was refuted by Kountouras et al. (82) who had previously 249 
found that successful eradication of  H. pylori infection was associated with significantly 250 
lower mortality risk in AD patients [HR (95% Cl)=0.287 (0.114-0.725), p=0.008] (83). 251 
 252 
ORAL BACTERIA RELATED TO AD 253 
The oral cavity harbours an impressive range of bacterial phylotypes (84). Molecular 254 
identification methods have detected close to 900 different predominant bacterial species of 255 
which 35% cannot yet be cultured (85). The oral microbiome profiles appear to be 256 
individualized (86), meaning that bacterial microbiomes can vary both qualitatively and 257 
quantitatively between individuals, although there are also significant overlaps. Each 258 
individual can harbour harbor up to 200 different bacterial taxa in their mouth and there is a 259 
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variation in the microbiota in different oral sites (84, 87). Furthermore, the composition of the 260 
oral microbiota irrespective of being indigenous or pathogenic in the oral cavity keeps 261 
changing in view of major oral diseases (caries, gingivitis, aggressive and chronic 262 
periodontitis, periodontal-endodontic lesions, peri-implantitis and mucositis) (88-94). 263 
Particularly plaque-induced oral diseases such as periodontitis are associated with a change in 264 
the oral microbiota. There is a predominance of anaerobic bacteria in the oral cavity. Many of 265 
the major periodontal microorganisms are anaerobic, e.g., Porphyromonas gingivalis, 266 
Treponema denticola and Tannerella forsythia. The abundance of anaerobes tend to increase 267 
with the development of plaque-induced oral diseases.  268 
 269 
Periodontal bacterial pathogens are related to AD 270 
Major pathogens of chronic periodontitis such as P. gingivalis, T. forsythia, and T. denticola 271 
are implicated in the development of several inflammatory diseases at remote organ sites. 272 
Except for T. forsythia, all the above three of the above-named organisms of which T. 273 
denticola represents a spirochetes, have been found in the AD brain (5, 8). Spirochetes are 274 
strongly neurotropic. They can spread along nerve fibers and via lymphatics (67, 68) and have 275 
been detected in the trigeminal nerve and trigeminal ganglia (95). Spirochetes and their 276 
antigens as well as DNA have been found associated with AD and are strongly implicated as 277 
the causative agents leading to dementia (68, 69). In 14 studies spirochetes were detected in 278 
AD by different authors in different laboratories and countries by means of different 279 
techniques (for a reviews see Miklossy (68, 69). Riviere et al. (5) demonstrated the presence 280 
of seven different oral Treponema species in 14 out of 16 AD brain specimens (Fig. 3). 281 
Spirochetes were even cultivated from the brains of AD patients indicating that they were 282 
viable in the brain (67, 68, 77). Miklossy suggested a co-infection by several spirochetes in 283 
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AD including the oral varieties (T. socranskii, T. pectinovorum, T. denticola, T. medium, T. 284 
amylovorum and T. maltophilum) as demonstrated by Riviere et al. (5). Spirochetes 285 
reproduced the biological and pathological hallmarks of AD after exposure of mammalian 286 
neuronal and glial cells in organotypic cultures (68, 69). 287 
It has been was demonstrated that LPS from periodontal bacteria can access the AD brain 288 
during life as while detection in corresponding controls, with equivalent or longer postmortem 289 
interval was absent (8). This study supports the literature on elevated antibodies to periodontal 290 
disease-associated bacteria such as P. gingivalis, being found in AD patients (7). Furthermore, 291 
in 2,355 people 60 years and over, the third NHANES study found associations between 292 
periodontitis and cognitive impairment and between measures of immunoglobulin to P. 293 
gingivalis and cognitive test performance (96, 97) used cohort methodology analyzing serum 294 
levels of antibodies to periodontal disease. All In this study all participants were cognitively 295 
intact at baseline. Those who went on to develop AD had higher levels of serum antibodies to 296 
periodontal pathogens at baseline. This The study sugggested suggested a temporal 297 
periodontal disease came before AD.   298 
Other important periodontal pathogens related to AD are Fusobacterium nucleatum and 299 
Prevotella intermedia. In the NHANES study antibody Antibody levels to these organisms 300 
were significantly increased (α = 0.05) at baseline serum in patients with AD compared to 301 
controls (97). The results were significant after controlling for baseline age, Mini-Mental 302 
State Examination score, and allele APOEɛ4 status. Noble et al. (98) found that a high anti-303 
Actinomyces naeslundii titer (> 640 ng/ml, present in 10% of the subjects) was associated 304 
with increased risk of AD (HR = 2.0, 95% CI: 1.1-3.8). This association was stronger after 305 
adjusting for other significant titers (HR = 3.1, 95%CI: 1.5-6.4) and confirmed that periodontal 306 




Possible consequences to the brain of carrying oral bacterial pathogens  309 
The fact that inflammation is sustained in the AD brain suggests that local immunogenic 310 
hallmark proteins and/or peripheral infections are key perpetrators. This is supported by 311 
reports highlighting microorganisms and their toxic products as well as DNA in brain tissue 312 
of AD patients and experimental animals (see later below). Bacteria activate pathways that 313 
include the integrin receptor CR3 (CD11b/CD18) and TLR signalling (99) and the 314 
complement cascade (100). The NF-κB signalling pathway for cyto/chemokine release (TNF-315 
α, IL-8) (101) produces free radicals, nitric oxide triggers and apoptosis (102). The oral 316 
cavity, lungs and gastrointestinal and urinary tracts are plausible sources of brain 317 
microorganisms. The likely passage of the microorganisms of interest from their original sites 318 
to the brain is described below. 319 
Infections with spirochetes can cause cerebral hypoperfusion (103), cerebrovascular lesions 320 
and a severely disturbed capillary network (68, 69).  Chronic spirochetal infections can also 321 
induce slowly progressive dementia, cortical atrophy, chronic inflammation and Aβ 322 
deposition, which cannot be distinguished indistinguishable from that occurring in AD brains 323 
(for reviews see 68, 69, 72). Furthermore, cultured neuronal cells exposed to spirochetes 324 
produce Aβ (104). Spirochetes are also able to form plaque-, tangle- and curly fiber-like 325 
lesions (72, 105). They induce a latent and slowly progressive infection by evading host 326 
defenses. This promotes their survivial and proliferation in the brain by blocking the 327 
complement cascade. Spirochetes may even survive and proliferate in hosts that are immune-328 
competent.  By evading host’s defenses, spirochetes induce a latent and slowly progressive 329 
infection to promote their survival and proliferation in the brain and by blocking the 330 
complement cascade spirochetes may survive and proliferate even in hosts that are immuno-331 
competent. Interestingly, the remarkable ability of T. pallidum to evade clearance from the 332 
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immune system has earned it the designation “stealth pathogen” (106). Also anThe activated 333 
complement cascade can be seen following spirochete infections (11) which may be used as a 334 
non-specific marker of CNS inflammation. Spirochete-host interactions initiate and sustain 335 
chronic inflammation triggering various immune responses that activate and end up with 336 
various immune responses activating the innate and adaptive immune system, free radicals 337 
production, apoptosis and amyloid deposition typically seen in AD brains (107).  338 
P. gingivalis has been designated as one of the “keystone” periodontal pathogens because it is 339 
able to establish and maintain the periodontal disease-associated “inflammophillic” 340 
microbiota (108). It is able to perform this task as it possesses an awesome variety of 341 
virulence factors, recently reviewed by Singhrao et al. (109), to evade the host immune 342 
defenses, thus serving two major functions: initially for survival of P. gingivalis itself via a 343 
sustainable inflammatory milieu and then to satisfy its sustainment of nutritional sources by 344 
eliminating microbial competitors needs and to stamp out competition (108).  345 
The P. gingivalis endotoxin LPS demonstrates differences in the number of phosphate groups 346 
together with both the amount of lipid A fatty acids and their specific position. The presence 347 
of multiple lipid A structures makes it more difficult for the innate host responses to recognise 348 
recognize the molecule thereby aiding the virulence of P. gingivalis (110). The consequences 349 
of finding P. gingivalis LPS in the host’s body, e.g. the brain (8), are include priming of 350 
cells for differential activation of the TLR-mediated NF-κB signalling pathway (111) leading 351 
to cytokine liberation, complement activation and maintenance of intracerebral inflammation. 352 
P. gingivalis evades circulating phagocytes by adhering to erythrocytes (112). An active 353 
invasion of P. gingivalis and infection-induced complement activation with bystander neural 354 
injury was detected in the brains of ApoE-/- mice (113). This supported previous notions that 355 
bacterial infections can contribute to the development of AD pathology via mechanisms 356 
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involving acute phase proteins such as cytokines and the complement cascade where neurons 357 
would be attacked.  358 
 359 
ORAL VIRUS RELATED TO AD 360 
Herpes simplex virus (HSV) is present in more than 70% of the population after 50 years age 361 
(114-116). It persists latently in the peripheral nervous system and is periodically reactivated. 362 
Characteristically, HSV-1 has been designated as the enemy within (10). Herpes viruses, 363 
including Epstein-Barr virus and cytomegalo virus, are found in high copy counts in 364 
aggressive periodontitis, and may interact synergistically with periodontopathic bacteria in the 365 
pathogenesis of this disease (117). Periodontal infections activated by Herpes virus Herpes 366 
virus active periodontal infections may impair local host defenses and thus increase the 367 
aggressiveness of resident periodontopathic bacteria. The bacteria, in turn, may augment the 368 
virulence of the herpes viruses.  369 
High proportions of viral-associated proteins in amyloid-containing plaques and/or NFTs 370 
corroborate with the involvement of HSV-1 in AD pathology (118). This supports a study by 371 
Notably, De Chiara et al. (119) who found reported an association between Aβ accumulation 372 
in the brain and HSV infection. Itzhaki et al. (120) suggested that not only does HSV-1 373 
produce the main components of amyloid plaques and NFTs (i.e. Aβ and 374 
hyperphosphorylated tau), but it also interferes with the autophagic events that prevent 375 
degradation of these proteins and eventually leading to their accumulation in the AD brain. 376 
Further, in vitro and in vivo investigations using mouse in murine models following HSV-1 377 
demonstrated Aβ accumulation (121).  378 
A number of scientists have suggested that there is imbalance between production and 379 
clearance of β-amyloid in the brain, a thought premise first proposed by Wisniewski et al. 380 
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on the discovery of soluble species of this protein and later confirmed by Zlokovic et al. (123) 381 
(123) to be the case. Thus it It is now widely accepted that defective clearance of this protein 382 
brains that leads leading to its accumulation in the form of insoluble Aβ40/42 plaques. 383 
and cytomegalovirus have been detected in the brains of older adults with and without AD 384 
(124-126), HSV-1 viral DNA is present in a higher proportion of AD patients (127). It is 385 
particularly seen in the temporal and frontal cortices which are the brain regions that are most 386 
damaged in AD (128, 129). The relevance of this association is still under investigation; 387 
however a plausible role for the HSV-1 viral DNA could be in associated with the plaque 388 
maturation process. Jamieson et al. (127) found that the virus was absent from the brains of 389 
most young people, probably because it enters the brain during old age either when the 390 
senescence (130) or the virus itself is initially responsible for weakening the host’s immune 391 
defenses first. This latter explanation is likely and is supported by us and others (131).  392 
HSV-1 is a strong risk factor for AD in the brains of those with the APOEɛ4 allele (125, 132). 393 
This virus is not only a dormant passenger but can persist in the latent form in neurons or 394 
replicate at a very low level in neuroglia (133). During persistence it may release toxic 395 
products continuously and induce pro-inflammatory cytokines at low levels which become an 396 
additional burden to the a host who is already challenged by age, poor diet, failing restricted 397 
exercise as well as any genetic susceptibilities. Itzaki and Wozniak (10) suggested that stress 398 
or peripheral infection can reactivate the virus periodically from latency in the brain. This 399 
may cause an acute but presumably localized infection, and subsequent damage modulated by 400 
the APOɛ gene can lead to formation of Aβ plaques and NFTs. 401 
The presence of anti-HSV IgM, a sign of reactivated infection, almost doubled the risk for AD 402 
while anti-HSV IgG did not influence the risk (134). Kobayashi et al. (135) suggested that the 403 
anti-HSV-1 Ig antibody avidity index could be a useful biomarker for early diagnosis of 404 
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anamnestic mild cognitive impairment, which is prodromal to AD, as well as for AD 405 
sufferers. 406 
Reactivation of HSV seropositivity is highly correlated with incident-AD (136). Letenneur et 407 
al. (136) speculated that AD pathology starts many years before frank dementia and recurrent 408 
reactivation of HSV can act as a potent stimulus to brain microglia, increasing cytokine 409 
levels, and triggering a positive feedback cycle leading to increasing accumulation of 410 
neurohistopathological changes. In other words, infection, followed by local CNS 411 
inflammatory reaction is the likely primary occurrence stimulus wheras proteostasis is a 412 
consequence of the primary event leading to the development of AD. 413 
Hill et al. (137) suggested a role for HSV-1-induced miRNA-146a in the evasion of HSV-1 414 
from the complement system. which This which is a major first-line host defense mechanism, 415 
and the activation of key elements in the arachidonic acid cascade known to contribute to AD-416 
type neuropathological changes. 417 
 418 
ORAL YEASTS RELATED TO AD 419 
Oral yeast infection is represents a secondary opportunistic infection disease of the diseased 420 
where particularly involving Candida albicans, but increasingly also non-albicans species, 421 
e.g. Candida glabrata are involved. With a growing population of elderly, severe systemic 422 
fungal infections have increased dramatically in this age group during the last 30 years (138, 423 
139). Oral yeasts can be found in periodontal pockets, in root canals, on the mucosae and 424 
underneath dentures (denture stomatitis) (140-142). Denture stomatitis is prevalent in elderly 425 
wearing dentures that are heavily contaminated with yeasts which can be a source of systemic 426 
mycosis (Fig. 3). Disseminated mycoses have recently been reported in AD patients (143, 427 
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144). Fungal molecules including proteins and polysaccharides [(1,3)-β-glucan] were detected 428 
in peripheral blood serum, and fungal proteins and DNA were demonstrated by PCR in brain 429 
tissue of AD patients. Also chitinChitin-like fungal structures have also been found in the AD 430 
brain (145) and chitinase activity has been proposed as a powerful biomarker of AD (146). 431 
Immunohistochemical analyses revealed, albeit in a few cells, in In AD brains,  , containing 432 
cytoplasmic material in a small number of cell cells were was targeted by antibodies with 433 
immunoreactivity to that immunoreacted with antibodies raised against some yeast cells 434 
(147). These findings were consistent with the idea that neurons can be infected by fungi. 435 
Interestingly, antifungal treatment reversed the clinical symptoms of some AD patients (148, 436 
149). 437 
 438 
HOW DO ORAL MICROORGANISMS REACH THE BRAIN? 439 
Blood stream dissemination 440 
The most likely pathway of for dissemination for of oral microorganisms to the brain is 441 
through the blood stream (150). Dental treatment procedures as well as brushing, flossing, 442 
chewing and use of tooth picks in a patient with periodontitis will release a bacteraemia (151). 443 
This can occur several times during the day and has been estimated to last for up to 3 hours 444 
for oral bacteria (152). The bacteraemia is usually taken care of contained by immune cells of 445 
the body. However, in people with reduced immune defense, e.g. older individuals, bacteria 446 
may settle down within localize to crevices of the oral cavity and vascular channels (150).  447 
The blood- brain barrier 448 
An intact blood-brain barrier (BBB) prevents microorganisms in the blood from accessing the 449 
brain. However, aging favors overgrowth of oral microorganisms, particularly anaerobic 450 
bacteria and facultative yeasts that established earlier in life and provoked pro-inflammatory 451 
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responses that weakened the BBB (16). ActuallyNotably, magnetic resonance imaging (MRI) 452 
confirmed loss of BBB integrity in a mouse model of disseminated candidosis (153). Loss of 453 
integrity allows microorganisms to spread through the blood stream and quietly contribute in 454 
the pathogenesis of AD. During immunosenescence, the innate immune system gradually 455 
takes over for the acquired immune system. This contributes to a rise in circulating 456 
proinflammatory cytokines such as TNF-α (16).  Indeed, proinflammatory mediators can 457 
cross the BBB (3, 7, 154). APOEɛ4, TNF-α  and perhaps Ephrin Type-A Receptor 1 (EphA1) 458 
may influence BBB integrity and thus be important for penetration of bacteria, LPS and other 459 
toxic bacterial products as well as yeasts into the brains of AD patients (16).  APOEɛ4 affects 460 
the integrity of the BBB by activating the cyclophilin A matrix metalloproteinase MM-9 461 
pathway (155). 462 
 It is also plausible to suggest that the permeability of the BBB increases with age and thus 463 
promotes AD pathogenesis making the brain accessible to microorganisms. Mice with a 464 
mutation in the amyloid precursor protein gene which is related to early-onset AD in man, 465 
showed increased permeability of the BBB and increased formation of senile plaque as 466 
compared to control mice (156). The changes increased with age.  467 
 468 
Circumventricular organs and perivascular spaces 469 
Circumventricular organs (permit polypeptide hypothalamic hormones to leave the brain 470 
without disrupting the BBB) are not dependent on the BBB (56) and may act as another entry 471 
portal to the brain for bacteria (157).  Poole et al. (8) postulated that bacteria and their 472 
products may also directly access the brain via the systemic circulation through the 473 
perivascular spaces.  474 
     475 
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The olfactory hypothesis 476 
The “olfactory hypothesis” suggests the olfactory tract as a potential route for pathogenic 477 
bacteria to enter the brain and thereby trigger the production of Aβ and NFTs (158). The 478 
olfactory and trigeminal nerves are known to be used by periodontal pathogens to bypass the 479 
BBB for direct passage to the CNS (5, 150, 159, 160). Identification of oral treponemes in the 480 
trigeminal ganglia supports such a route of dissemination (5). Further, sSpirochetes may also 481 
spread along the fila olfactoria and tractus olfactorius (68, 69).  482 
Olfactory unsheathing cells (OECs) engulf bacteria and migrate towards TNF-α released by 483 
activated astrocytes (161). Therefore, OECs could be a vehicle for transporting live bacteria to 484 
the brain (i.e., Trojan horse). The olfactory bulb was the first area where NFTs and Aβ 485 
deposition were detected in the neuropathological trajectory of AD in humans (162) and in 486 
mouse models of AD (163). 487 
 488 
GENETIC, NUTRITIONAL AND ENVIRONMENTAL FACTORS PROMOTING AD 489 
While early-onset AD is genetically determined, LOAD is thought to result from interaction 490 
between genetic and environmental factors (12). Several mutated genes are associated with 491 
the familial AD, such as the amyloid beta (Aβ) precursor protein (AβPP) gene and the 492 
presenelin-1 (PSEN-1) and PSEN-2 gene (164-166). A major risk factor for LOAD is 493 
polymorphism in the APOɛ4 allele (2). Also cytokine-related genes seem to be involved in the 494 
susceptibility to inflammation in both LOAD (167, 168) and periodontitis (169-171). Thus, 495 
polymorphisms that increase TNF-α also increase the risk of both AD and periodontitis (172, 496 
173). Lambert et al. (174) found that 20 different loci can increase host susceptibility to AD 497 
including polymorphisms in genes associated with interleukin-1 (IL-1) (71, 175-178) and 498 
TNFα (71, 172, 179-181). The APOɛ4 gene which is one of these 20 loci is highly correlated 499 
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with AD (182) but it is also a risk factor for infection and increases the expression of 500 
inflammatory mediators (11). Recently, genetic overlap between AD, C-reactive protein 501 
(CRP) and plasma lipids was demonstrated by using summary statistics from GWAS of over 502 
200,000 individuals (183). There may also be interplay between genetic risk and 503 
environmental risk factors such as toxins and or bacterial, viral and fungal pathogens in 504 
LOAD reflecting its complex and multifactorial etiology (1). 505 
Diet with its content of essential B-vitamins, phospholipids and other micronutrients are 506 
important for forming new nerve synapses (184). Nutritional deficiencies are common both in 507 
elderly and in dementia subjects as briefly discussed by Singhrao et al. (150). 508 
 509 
ASSOCIATION BETWEEN CHRONIC PERIODONTAL DISEASE AND AD 510 
There is increasing evidence for an association between chronic periodontitis and LOAD 511 
(185). Cross-sectional and longitudinal studies have demonstrated that gingival bleeding, loss 512 
of periodontal attachment, periodontal probing depth, alveolar bone loss and antibodies to 513 
periodontal pathogens are significantly associated with lower cognitive function and decline 514 
after adjustment for co-variates (for a review see (12)). Acute phase proteins, including 515 
cytokines are possible indirect links between periodontal pathogens and/or their virulence 516 
factors (12, 13). Elderly often show neglect of oral hygiene (Figs. 3-5) which can stimulate 517 
recurrent chronic oral infection (150). This again promotes inflammation which can lead to 518 
confusion and dementia (3, 4, 154). In 152 subjects 50-70 years of age who were followed for 519 
20 years, greater levels of periodontal inflammation correlated with lower cognitive levels 520 
(186). Furthermore, gingival bleeding and loss of periodontal attachment apparatus were 521 
associated with cognitive impairment in a cohort of 5,138 people aged 20-59 years (187). In 522 
144 nuns, those with encoding APOEɛ4 and who had fewer teeth had experienced more rapid 523 
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decline than those with neither or either of these risk factors (188). Clinical and 524 
epidemiological studies showed that loss of teeth is associated with poor memory (6, 96, 187, 525 
189). In another study with of 597 community dwelling men followed for 32 years, tooth loss, 526 
increasing periodontal pockets depths and progression of alveolar bone loss were associated 527 
with impaired cognition particularly in those over 45 years of age (190). Recently, de Souza 528 
Rolim et al. (191) found that periodontal infections were more frequent in patients with mild 529 
AD than in healthy subjects. Another interesting feature related to the pathogenesis of AD is 530 
the low level of infection by “commensals on the loose” (16). These “immuno-tolerated” 531 
bacteria may silently multiply in sites outside of their primary niche and an ongoing illness 532 
at their secondary location may have significant deleterious effects upon the health of the 533 
elderly or demented host with an existing immunocompromised status.  534 
 535 
PUTATIVE TREATMENT AND PROPHYLAXIS OF AD 536 
There is no effective treatment or prophylaxis yet for AD, but several approaches have been 537 
proposed. Efforts in this respect are important. If we could delay onset of dementia by only 2 538 
years we might lower the prevalence of AD by more than 22 million cases over the next 40 539 
years (14). Indeed, delaying the disease process is a better option as the NotableyNotably, the 540 
of the APOEɛ4 allele in the very old (90+) age group, appears to confer protection (192), 541 
having bypassed a period of being at risk around 85+ years of age. 542 
If periodontal disease is implicated in AD, periodontitis prophylaxis should be feasible could 543 
be of help. It would be interesting to see if this has any effect on the initiation and aggravation 544 
of AD but an observation period of decennia is probably needed. 545 
In a study of subjects with mild to moderate AD, a A 3-month course of doxycycline and 546 
rifampicin reduced cognitive deterioration in during a 6 months’ follow-upfollow-up interval 547 
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study in subjects with mild to moderate AD (193). It was concluded that use of antibacterial 548 
the treatment of C. pneumoniae but had a beneficial effect on cognitive decline in AD (193). 549 
This might be related to prevention or attenuation of a number of peripheral infections or 550 
dampening down the proinflammatory cytokine response. MinicyclineMinocycline was found 551 
early, pre-plaque neuroinflammation and inhibit the APP cleaving enzyme 1 (BACE-1) in a 552 
transgenic model of Alzheimer's disease-like amyloid pathology (194). It was suggested that 553 
interfering with inflammation could be a useful therapeutic approach in early, pre-plaque 554 
stages of AD-like amyloid pathology. 555 
Anti-inflammatory drugs given for at least 2 years before the onset of dementia delayed the 556 
disease process (194195-196197). It may also be beneficial to combine anti-inflammatory 557 
antibacterials (193). Examination of several available Non-steroidal Anti-Inflammatory Drugs 558 
(NSAIDs) showed that only a few of them had any useful Aβ-modifying or other activity of 559 
therapeutic use in LOAD (for a review see (1)).  560 
Itzhaki and Wozniak (10, 197198) suggested that antiviral therapy and perhaps vaccination 561 
against HSV-1 in early life could be useful. If HSV-1 is implicated in AD, vaccination could 562 
prevent the excessive accumulation of Aβ in the brain. Vaccination with mixed HSV 563 
glycoproteins prior to HSV infection protected against viral latency in mouse brains (198199). 564 
Also Mori (199200) maintained that antiviral approaches including chemotherapy and 565 
vaccination are promising for prevention and treatment of AD and remain to be validated. 566 
Furthermore, Carter (118) suggested that vaccination or antiviral agents and immune 567 
suppressants may be considered as therapeutic options before or in during the early stages of 568 
AD. Interestingly, exposure of HSV-1-infected cell cultures to intravenous immunoglobulin 569 
acting via anti-β-amyloid antibodies,antibodies reduced the accumulation of Aβ and 570 
phosphorylated tau (200201).  571 
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Angiotensin-converting enzyme (ACE) from Stigmatella aurantiaca may cleave the Aβ 572 
peptide similar to human ACE and may be used as a novel form of treatment against AD 573 
(201202). Furthermore, Chiarini et al. (202203) maintained that calcilytics could halt AD 574 
progression and preserve the patients' cortical neurons, cognitive abilities, and eventually life 575 
if given at minimal cognitive impairment or at earlier stages. Studies from using mice 576 
suggested the use of tau aggregation inhibitors as potential drugs for the treatment of AD and 577 
other tauopathies (203204).  578 
Resveratrol is a polyphenol present in red wine. Its capability of directly interfering with the 579 
toxic β-amyloid protein aggregation in AD has recently been shown (204205). Resveratrol 580 
was found to reduce Aβ-induced toxicity in a Caenorhabditis elegans model of AD by 581 
targeting specific proteins involved in proteostasis and thereby reducing the amount of 582 
aggregated Aβ (205206). This is in concert with our previous finding that the effect of a 583 
drinking pattern of 2-7 times per week reduced the risk of myocardial infarction among men 584 
who had a history of tooth extractions due to periodontal/dental infection (206207). 585 
Potent inhibitors of Aβ oligomer formation or Aβ-induced cell toxicity have proven to be 586 
attractive means for therapeutic intervention of AD.  Song et al. (207208) found that the anti-587 
Alzheimer effects of centipedegrass, which contains several C-glycosyl flavone constituents, 588 
occurred through inhibition of neuronal cell death by intervening with oligomeric Aβ 589 
formation and reducing beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) 590 
activity. The authors suggested that Maysin, a major flavonoid of corn silk, in centipedegrass 591 
could be an excellent therapeutic candidate for the prevention of AD. 592 
Active immunization against important domains of Alzheimer tau eliminated tau aggregation 593 
and neurofibrillary pathology (208209). The AD type of tau hyperphosphorylation was 594 
abolished in transgenic mice by vaccination across a wide range of AD phospho-epitopes. 595 
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Kontsekova et al. (208209) demonstrated that active immunization of rats with a tau peptide 596 
encompassing the epitope revealed by monoclonal antibody DC8E8 led to elimination of all 597 
major hallmarks of neurofibrillary pathology involving a 95% reduction in the AD-type 598 
hyperphosphorylation of tau. 599 
 600 
CONCLUSIONS 601 
LOAD which is the predominant form of AD, does not seem to have a single cause. On the 602 
contrary, a multitude of factors may be involved and they may act in concert. Of theseAmong 603 
others , both genetic and environmental factors may be involved. Even among 604 
cooperation-action may occur since the brain can hardly differentiate between different 605 
microbial insults which collectively contribute capacity for enhancing all end up in 606 
Irrespective of the cause, systemic inflammation may predict the onset of dementia. 607 
Organisms such as spirochetes, P. gingivalis, C. pneumoniae, H. pylori, Hherpes simplex type 608 
virus and Candida are among the prime candidate pathogens the most suspected pathogens in 609 
events causing AD, oral microorganisms may play a role, particularly anaerobic bacteria such 610 
as treponemes, P. gingivalis, Prevotella spp., Fusobacterium and Actinomyces, but also 611 
facultative anaerobic Candida species. It is important to recognize that infection can occur 612 
decades before the manifestation of dementia. The most convincing evidence for a causal 613 
relationship between oral bacteria and AD is that noted for spirochetes which are both 614 
neurotropic and motile. They also fulfill Koch’s and Hill’s postulates for a causal relationship. 615 
It is likely that oral infection can be a risk factor for Alzheimer’s disease but it is not the only 616 
one. Experiments in humans in vivo may require long exposure times to disclose key events 617 
and mechanisms of AD. There is, as yet, no cure for AD despite concerted efforts and 618 
investment by industry.and this is not without concerted efforts from investment by industry 619 
but because drug discovery in dementia is hugely challenging. Prevention of AD through 620 
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long-term use of antibiotics may be impractical and could select for resistant bacteria. This is 621 
worrisome as the prevalence of AD and the public expenses related to its management are 622 
expected to increase greatly in the next decade.  623 
in AD, then dental hygiene and treatment will provide the AD prophylaxis from an early age 624 
this oral disease periodontitis is modifiable. However, improving oral hygiene and treating 625 
in the AD patient can be challenging since patients are often uncooperative.  There is also 626 
for training care-givers to assist with oral care in such patients.  627 
Vaccination against key organisms and important domains of AD has had some beneficial 628 
effect. Also several agents interfering directly with the pathogenesis of AD have been tested. 629 
In order to find a cure, there is a need for clinical diagnostic information and knowledge of 630 
the causal agents for AD AD causative agents so that specific treatment options targeting 631 
these organisms,  against these organisms, can be developed. As for diagnostic biomarkers, 632 
increased antibody levels to specific oral pathogens in particular to P. gingivalis may be used 633 
as a preventive monitoring tool years before clinical manifestation of AD. This is important 634 
because treatment will probably have to start early.  635 
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Fig. 1. The pathological hallmarks of AD, numerous extracellular amyloid-Aβ plaques 1244 
and intra-neuronal neurofibrillary tangles (NFTs). Although there are several NFTs, 1245 
only one is picked out in boxes at x 10 and x 40 objective lens magnification. 1246 
 1247 
Fig. 2. Immunofluorescence labelling (green dots) of hippocampal CA neurons 1248 
opsonised by iC3b following monoinfection with P. gingivalis at 24 weeks of APOɛ 1249 
gene knockout (ApoE−/−) mice. This is indirect evidence of an oral infection having 1250 
affected the host’s brain. 1251 
 1252 
Fig. 3. Photo of a Sabouraud agar model made from the upper denture of an old patient 1253 
with denture stomatitis and heavy accumulations of denture plaque on the fitting 1254 
surface. Candida species are growing profusely. 1255 
Fig. 3 Section of pons area of Alzheimer's disease brain from an 84-year-old female 1256 
subject (from ref. 5 with permission), demonstrates metabolically active Treponema 1257 
pectinovorum oral bacteria (arrows) stained dark blue following immunostaining with 1258 
anti-T. pectinovorum  using the avidin-biotin peroxidase method. 1259  60
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